Da Zhong Ri Bao·2026-01-04 09:27Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. is accelerating its transformation towards innovation-driven development by leveraging its strong technological foundation and research capabilities, contributing to the treatment of major diseases, particularly neurodegenerative diseases like Alzheimer's [1][3]. Group 1: Company Overview - Xinhua Pharmaceutical, as the first chemical synthesis pharmaceutical enterprise in New China, has become a significant global production and export base for antipyretic and analgesic drugs, with a deep focus on cardiovascular, anti-infection, and nervous system treatment areas [3]. - The company has established 26 products that hold the number one market share or are exclusive, with its products sold globally [3]. Group 2: Research and Development Initiatives - Xinhua Pharmaceutical has led the formation of the "Shandong Provincial Neurodegenerative Drug Research and Innovation Consortium" in collaboration with eight top institutions, targeting global medical challenges such as Alzheimer's disease [3]. - The consortium aims to create a comprehensive platform from disease mechanism research to clinical translation, focusing on the development of the first multi-target small molecule drug aimed at Aβ clearance for Alzheimer's disease [3]. - The drug OAB-14, currently in the clinical trial phase, has completed Phase I trials with good safety results, and Phase II trials are underway, marking a significant step in original drug development [3]. Group 3: Innovation and Talent Development - The company has built a closed-loop ecosystem driven by "talent-led innovation, innovation-driven industry, and industry feedback to education," supported by a high-end talent team led by 10 academicians and over 500 master's and doctoral graduates [4]. - Xinhua Pharmaceutical has established a national industry-education integration community with 110 institutions, training over 10,000 various talents in the past three years [4]. Group 4: Financial and Operational Achievements - Since the 14th Five-Year Plan, Xinhua Pharmaceutical has invested a total of 2 billion yuan in R&D, achieving 129 drug approvals, which is 5.4 times that of the 13th Five-Year Plan period [4]. - The company has set 71 national pharmaceutical industry standards and obtained 236 authorized patents, with the initial formation of three world-class bases for pharmaceutical intermediates, raw materials, and formulations [4]. - Xinhua Pharmaceutical has seen nearly 400 million USD in annual export revenue, with over 30 products passing international high-end certifications, enhancing the "International Xinhua" brand [4].